SBK1

Summary

SBK1 (SH3 domain binding kinase 1, HGNC:17699) is a protein-coding gene on chromosome 16p12.1, encoding Serine/threonine-protein kinase SBK1 (Q52WX2). May be involved in signal-transduction pathways related to the control of brain development.

Predicted to enable protein serine/threonine kinase activity. Predicted to be involved in chromatin remodeling. Predicted to be located in cytoplasm.

Source: NCBI Gene 388228 — RefSeq curated summary.

At a glance

• GWAS associations: 35
• Clinical variants (ClinVar): 55 total
• Druggable target: yes — 14 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001024401

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17699
Approved symbol	SBK1
Name	SH3 domain binding kinase 1
Location	16p12.1
Locus type	gene with protein product
Status	Approved
Aliases	Sbk
Ensembl gene	ENSG00000188322
Ensembl biotype	protein_coding
OMIM	620212
Entrez	388228

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000341901, ENST00000671413

RefSeq mRNA: 1 — MANE Select: NM_001024401 NM_001024401

CCDS: CCDS32416

Canonical transcript exons

ENST00000341901 — 4 exons

Exon	Start	End
ENSE00001374297	28318995	28319197
ENSE00001384457	28317385	28317617
ENSE00001386020	28320076	28323849
ENSE00001486676	28292525	28293300

Expression profiles

Bgee: expression breadth ubiquitous, 195 present calls, max score 98.21.

FANTOM5 (CAGE): breadth broad, TPM avg 8.2244 / max 361.8318, expressed in 774 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
153364	6.1109	738
153365	1.5608	526
153363	0.4811	239
153366	0.0717	34

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	98.21	gold quality
ganglionic eminence	UBERON:0004023	96.34	gold quality
cerebellar vermis	UBERON:0004720	95.23	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	91.25	gold quality
right hemisphere of cerebellum	UBERON:0014890	90.99	gold quality
quadriceps femoris	UBERON:0001377	90.41	gold quality
vastus lateralis	UBERON:0001379	90.21	gold quality
cerebellum	UBERON:0002037	89.93	gold quality
cerebellar cortex	UBERON:0002129	89.88	gold quality
cerebellar hemisphere	UBERON:0002245	89.80	gold quality
ventricular zone	UBERON:0003053	89.10	gold quality
biceps brachii	UBERON:0001507	88.83	gold quality
skeletal muscle tissue	UBERON:0001134	87.98	gold quality
thymus	UBERON:0002370	87.92	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	87.46	gold quality
postcentral gyrus	UBERON:0002581	86.67	gold quality
granulocyte	CL:0000094	86.48	gold quality
parietal lobe	UBERON:0001872	86.30	gold quality
secondary oocyte	CL:0000655	85.81	gold quality
hindlimb stylopod muscle	UBERON:0004252	85.80	gold quality
cardiac muscle of right atrium	UBERON:0003379	85.38	gold quality
occipital lobe	UBERON:0002021	85.30	gold quality
left ventricle myocardium	UBERON:0006566	85.26	gold quality
body of tongue	UBERON:0011876	85.08	gold quality
primary visual cortex	UBERON:0002436	85.07	gold quality
superior frontal gyrus	UBERON:0002661	84.33	gold quality
entorhinal cortex	UBERON:0002728	84.33	gold quality
deltoid	UBERON:0001476	84.30	silver quality
muscle tissue	UBERON:0002385	84.06	gold quality
tibialis anterior	UBERON:0001385	84.04	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.13

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

158 targeting SBK1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784

Literature-anchored findings (GeneRIF, showing 2)

• Results suggest that the wide-spread expression pattern of human SBK1 may predict a broad cellular function, and its dysregulation in certain cancers suggests an involvement of the protein in the pathogenesis of human cancers. (PMID:21104019)
• SH3 domain-binding kinase 1 promotes proliferation and inhibits apoptosis of cervical cancer via activating the Wnt/beta-catenin and Raf/ERK1/2 signaling pathways. (PMID:37132991)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	sbk1	ENSDARG00000056294
mus_musculus	Sbk1	ENSMUSG00000042978
rattus_norvegicus	Sbk1	ENSRNOG00000067387
drosophila_melanogaster	meng	FBGN0031855
drosophila_melanogaster	CG4945	FBGN0034137
caenorhabditis_elegans		WBGENE00011299
caenorhabditis_elegans		WBGENE00012726

Paralogs (1): SBK3 (ENSG00000231274)

Protein

Protein identifiers

Serine/threonine-protein kinase SBK1 — Q52WX2 (reviewed: Q52WX2)

Alternative names: SH3 domain-binding kinase 1

All UniProt accessions (2): A0A590UK17, Q52WX2

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in signal-transduction pathways related to the control of brain development.

Subcellular location. Cytoplasm.

Similarity. Belongs to the protein kinase superfamily. Ser/Thr protein kinase family.

RefSeq proteins (1): NP_001019572* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR016234	Ser/Thr_kinase_Sbk1	Family

Pfam: PF00069

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (12 total): sequence variant 4, region of interest 2, binding site 2, chain 1, domain 1, compositionally biased region 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q52WX2-F1	77.87	0.63

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 174 (proton acceptor)

Ligand- & substrate-binding residues (2): 59–67; 82

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 152 (showing top): GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, BILD_E2F3_ONCOGENIC_SIGNATURE, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, CUI_TCF21_TARGETS_2_UP, HUANG_DASATINIB_RESISTANCE_DN, XU_GH1_AUTOCRINE_TARGETS_DN, BOYLAN_MULTIPLE_MYELOMA_C_D_UP, chr16p12, LEIN_LOCALIZED_TO_DISTAL_AND_PROXIMAL_DENDRITES, CTGAGCC_MIR24, PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_DN, ATGTAGC_MIR221_MIR222, GOMF_PROTEIN_KINASE_ACTIVITY, GOMF_KINASE_ACTIVITY

GO Biological Process (1): protein phosphorylation (GO:0006468)

GO Molecular Function (7): protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein kinase activity	2
phosphorylation	1
protein modification process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

670 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SBK1	RIOK3	O14730	462
SBK1	TTC9B	Q8N6N2	451
SBK1	TANC1	Q9C0D5	445
SBK1	RBM28	Q9NW13	440
SBK1	IRGQ	Q8WZA9	433
SBK1	RGS7BP	Q6MZT1	430
SBK1	APOBR	Q0VD83	420
SBK1	PIP4K2B	P78356	411
SBK1	ABRACL	Q9P1F3	405
SBK1	RASSF3	Q86WH2	402
SBK1	DMAC2	Q9NW81	402
SBK1	SRC	P12931	388
SBK1	PLCXD2	Q0VAA5	386
SBK1	LRFN3	Q9BTN0	385
SBK1	INPP5A	Q14642	385

IntAct

2 interactions, top by confidence:

A	B	Type	Score
SBK1	FTL	psi-mi:“MI:0914”(association)	0.350

BioGRID (11): SBK1 (Co-fractionation), SBK1 (Biochemical Activity), SBK1 (Affinity Capture-RNA), GFER (Affinity Capture-MS), YTHDF1 (Affinity Capture-MS), FTL (Affinity Capture-MS), SBK1 (Affinity Capture-RNA), SBK1 (Affinity Capture-MS), SBK1 (Affinity Capture-MS), SBK1 (Affinity Capture-MS), SBK1 (Affinity Capture-MS)

ESM2 similar proteins: A4II32, A7MCT6, D3ZRW8, G5E872, O35465, O54783, O55229, P50747, P61797, Q14164, Q14318, Q14CH1, Q1JP61, Q3B7U9, Q496Y0, Q497B8, Q52WX2, Q5I0I5, Q7TQC5, Q7YRZ1, Q7YRZ2, Q7Z2E3, Q7Z695, Q80WC9, Q8BNV1, Q8BYN3, Q8CGA0, Q8HXH0, Q8IYL2, Q8IZ69, Q8K4H4, Q8N371, Q8NF37, Q8NI29, Q8QZX0, Q920N2, Q96EN8, Q9BGQ0, Q9CXT6, Q9D2Q2

Diamond homologs: A1A5Q6, A2XFF4, A7MB74, A8XJQ6, A8XW88, B1WAS2, B1WBU5, B8BBT7, C0HKC8, C0HKC9, G1X456, O61661, O70150, O88866, O94806, P00517, P05131, P05132, P05383, P05986, P06244, P06245, P0C263, P0C264, P0C5K0, P0C5K1, P0DP15, P12370, P16912, P17612, P21137, P22612, P22694, P25321, P27791, P34099, P36887, P45894, P57058, P57059

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

55 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	51
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

564 predictions. Top by Δscore:

Variant	Effect	Δscore
16:28317576:GCACC:G	donor_gain	1.0000
16:28317586:G:T	donor_gain	1.0000
16:28317600:T:TA	donor_gain	1.0000
16:28317601:G:GA	donor_gain	1.0000
16:28317613:CACAG:C	donor_loss	1.0000
16:28317617:GGTGA:G	donor_loss	1.0000
16:28317618:GTG:G	donor_loss	1.0000
16:28317619:T:A	donor_loss	1.0000
16:28318991:TCAG:T	acceptor_loss	1.0000
16:28318992:CA:C	acceptor_loss	1.0000
16:28318993:A:AG	acceptor_gain	1.0000
16:28318993:A:G	acceptor_loss	1.0000
16:28318994:G:GG	acceptor_gain	1.0000
16:28318994:GGC:G	acceptor_gain	1.0000
16:28319152:GGA:G	donor_gain	1.0000
16:28319153:GAG:G	donor_gain	1.0000
16:28319196:AGG:A	donor_loss	1.0000
16:28319197:GG:G	donor_loss	1.0000
16:28319198:G:A	donor_loss	1.0000
16:28319199:T:A	donor_loss	1.0000
16:28293298:CAGGT:C	donor_loss	0.9900
16:28293299:AG:A	donor_loss	0.9900
16:28293300:GG:G	donor_loss	0.9900
16:28293301:GTA:G	donor_loss	0.9900
16:28317384:G:GC	acceptor_loss	0.9900
16:28317562:G:GT	donor_gain	0.9900
16:28317586:G:GT	donor_gain	0.9900
16:28317587:A:T	donor_gain	0.9900
16:28317591:T:TA	donor_gain	0.9900
16:28317603:TCTAC:T	donor_gain	0.9900

AlphaMissense

2713 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:28317575:G:A	G62S	1.000
16:28317575:G:C	G62R	1.000
16:28317575:G:T	G62C	1.000
16:28317584:G:A	G65R	1.000
16:28317584:G:C	G65R	1.000
16:28317584:G:T	G65W	1.000
16:28317585:G:A	G65E	1.000
16:28317585:G:T	G65V	1.000
16:28317597:T:C	L69P	1.000
16:28319007:C:A	A80E	1.000
16:28319010:T:C	L81P	1.000
16:28319012:A:C	K82Q	1.000
16:28319012:A:G	K82E	1.000
16:28319013:A:T	K82M	1.000
16:28319014:G:C	K82N	1.000
16:28319014:G:T	K82N	1.000
16:28319026:G:C	K86N	1.000
16:28319026:G:T	K86N	1.000
16:28319048:T:C	F94L	1.000
16:28319049:T:C	F94S	1.000
16:28319050:C:A	F94L	1.000
16:28319050:C:G	F94L	1.000
16:28319057:G:A	E97K	1.000
16:28319058:A:T	E97V	1.000
16:28319142:T:A	V125D	1.000
16:28319175:T:C	L136P	1.000
16:28319177:T:C	F137L	1.000
16:28319179:T:A	F137L	1.000
16:28319179:T:G	F137L	1.000
16:28320080:G:A	G145E	1.000

dbSNP variants (sampled 300 via entrez): RS1000013055 (16:28297609 A>T), RS1000101226 (16:28310132 C>T), RS1000181170 (16:28270913 G>T), RS1000187056 (16:28302826 C>G,T), RS1000269928 (16:28268008 G>A), RS1000296671 (16:28279321 C>G), RS1000340692 (16:28267799 A>C), RS1000384268 (16:28321109 G>A), RS1000439136 (16:28314840 A>G), RS1000445908 (16:28284808 T>C), RS1000492442 (16:28297332 A>G), RS1000501031 (16:28289487 C>A,T), RS1000555836 (16:28284138 C>T), RS1000708766 (16:28303480 T>C), RS1000772769 (16:28285190 C>T)

Disease associations

OMIM: gene MIM:620212 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

35 associations (top):

Study	Trait	p-value
GCST002783_101	Body mass index	5.000000e-06
GCST002783_183	Body mass index	2.000000e-09
GCST002783_336	Body mass index	1.000000e-09
GCST002783_586	Body mass index	5.000000e-06
GCST003097_27	Pediatric autoimmune diseases	4.000000e-09
GCST003435_31	Body fat percentage	1.000000e-08
GCST003435_41	Body fat percentage	7.000000e-07
GCST003995_17	Tonsillectomy	5.000000e-11
GCST004065_103	Waist circumference	2.000000e-07
GCST004065_93	Waist circumference	2.000000e-06
GCST004065_98	Waist circumference	2.000000e-11
GCST004066_126	Hip circumference	4.000000e-09
GCST004066_48	Hip circumference	2.000000e-07
GCST004495_96	BMI (adjusted for smoking behaviour)	3.000000e-08
GCST004497_38	Body mass index (joint analysis main effects and smoking interaction)	4.000000e-07
GCST004499_99	BMI in non-smokers	3.000000e-06
GCST004519_9	Body mass index (adult)	9.000000e-06
GCST004557_242	Body mass index	4.000000e-08
GCST004557_31	Body mass index	3.000000e-08
GCST004558_162	Body mass index (joint analysis main effects and physical activity interaction)	2.000000e-07
GCST004558_28	Body mass index (joint analysis main effects and physical activity interaction)	4.000000e-08
GCST004559_106	Body mass index in physically active individuals	5.000000e-07
GCST004559_24	Body mass index in physically active individuals	3.000000e-07
GCST005014_86	Tonsillectomy	5.000000e-11
GCST005316_465	Intelligence (MTAG)	2.000000e-13
GCST005316_514	Intelligence (MTAG)	5.000000e-08
GCST005316_515	Intelligence (MTAG)	7.000000e-11
GCST005752_47	Systemic lupus erythematosus	1.000000e-06
GCST006269_379	General cognitive ability	1.000000e-10
GCST008757_46	Alcohol consumption	1.000000e-10

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0007800	body fat percentage
EFO:0007924	tonsillectomy risk measurement
EFO:0004318	smoking behavior
EFO:0008002	physical activity measurement
EFO:0004337	intelligence
EFO:0008111	diet measurement
EFO:0004346	neuroimaging measurement
EFO:0004530	triglyceride measurement
EFO:0004533	alkaline phosphatase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1163129 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

14 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 365,673 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1173655	AFATINIB	4	15,144
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1789941	RUXOLITINIB	4	11,547
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL5416410	DASATINIB	4	655
CHEMBL553	ERLOTINIB	4	108,300
CHEMBL601719	CRIZOTINIB	4	14,403
CHEMBL939	GEFITINIB	4	117,814
CHEMBL522892	DOVITINIB	3	4,944
CHEMBL603469	LESTAURTINIB	3
CHEMBL1721885	SU-014813	2	363
CHEMBL475251	R-406	2	762
CHEMBL1908397	KW-2449	1	622

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — NKF1 family

ChEMBL bioactivities

23 potent at pChembl≥5 of 23 total, top 23 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.49	Kd	3.2	nM	STAUROSPORINE
7.68	Kd	21	nM	TAE-684
7.03	Kd	93	nM	R-406
7.00	IC50	99.8	nM	STAUROSPORINE
6.96	Kd	110	nM	NINTEDANIB
6.88	IC50	133	nM	STAUROSPORINE
6.71	IC50	193	nM	STAUROSPORINE
6.70	Kd	200	nM	SUNITINIB
6.70	Kd	200	nM	LESTAURTINIB
6.25	Kd	560	nM	GEFITINIB
6.24	Kd	580	nM	KW-2449
6.21	Kd	620	nM	SU-014813
6.10	Kd	790	nM	FEDRATINIB
6.00	IC50	1000	nM	TP-030-1
6.00	IC50	1000	nM	TP-030-2
6.00	IC50	1000	nM	TP-030n
5.92	Kd	1200	nM	DASATINIB
5.92	Kd	1200	nM	ERLOTINIB
5.89	Kd	1300	nM	CRIZOTINIB
5.89	Kd	1300	nM	RUXOLITINIB
5.82	Kd	1500	nM	DOVITINIB
5.51	Kd	3100	nM	CHEMBL1908395
5.32	Kd	4800	nM	AFATINIB

PubChem BioAssay actives

20 with measured affinity, of 144 total; 17 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	624812: Binding constant for SBK1 kinase domain	kd	0.0032	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	624812: Binding constant for SBK1 kinase domain	kd	0.0210	uM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	624812: Binding constant for SBK1 kinase domain	kd	0.0930	uM
methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate	624812: Binding constant for SBK1 kinase domain	kd	0.1100	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	624812: Binding constant for SBK1 kinase domain	kd	0.2000	uM
Sunitinib	624812: Binding constant for SBK1 kinase domain	kd	0.2000	uM
Gefitinib	624812: Binding constant for SBK1 kinase domain	kd	0.5600	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	624812: Binding constant for SBK1 kinase domain	kd	0.5800	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	624812: Binding constant for SBK1 kinase domain	kd	0.6200	uM
Fedratinib	624812: Binding constant for SBK1 kinase domain	kd	0.7900	uM
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide;hydrate	624812: Binding constant for SBK1 kinase domain	kd	1.2000	uM
Erlotinib	624812: Binding constant for SBK1 kinase domain	kd	1.2000	uM
Crizotinib	624812: Binding constant for SBK1 kinase domain	kd	1.3000	uM
Ruxolitinib	624812: Binding constant for SBK1 kinase domain	kd	1.3000	uM
4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one	624812: Binding constant for SBK1 kinase domain	kd	1.5000	uM
5-cyano-N-[2-(cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]piperidin-4-yl]phenyl]-1H-imidazole-2-carboxamide;hydrochloride	624812: Binding constant for SBK1 kinase domain	kd	3.1000	uM
Afatinib	624812: Binding constant for SBK1 kinase domain	kd	4.8000	uM

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
methylmercuric chloride	increases expression, affects cotreatment	3
Valproic Acid	increases methylation	3
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	2
6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	decreases expression	1
lasiocarpine	increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
bisphenol A	increases methylation	1
butyraldehyde	increases expression	1
tobacco tar	decreases expression	1
hydroquinone	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
pentanal	increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
nutlin 3	increases expression, affects cotreatment	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	decreases expression	1
Vorinostat	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Aldehydes	increases expression	1
Calcitriol	increases expression	1
Camptothecin	increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Dactinomycin	affects cotreatment, increases expression	1
Estradiol	affects cotreatment, decreases expression	1

ChEMBL screening assays

97 unique, capped per target: 97 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1167697	Binding	Inhibition of SBK1 at 1 uM	Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. — Bioorg Med Chem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TK07	HAP1 SBK1 (-) 1	Cancer cell line	Male
CVCL_TK08	HAP1 SBK1 (-) 2	Cancer cell line	Male
CVCL_TK09	HAP1 SBK1 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.